Panel Identification. Upon Panel Identification, Biogen Idec shall pay to AVEO five million U.S. dollars ($5,000,000). “Panel Identification” shall mean the first identification and in vitro and biochemical characterization of a panel of erbB3-specific murine antibodies.
Appears in 3 contracts
Sources: Option and License Agreement (Aveo Pharmaceuticals, Inc.), Option and License Agreement (Aveo Pharmaceuticals Inc), Option and License Agreement (Aveo Pharmaceuticals Inc)